US20130345147A1 - Prevention and treatment of ocular side effects with a cyclosporin - Google Patents

Prevention and treatment of ocular side effects with a cyclosporin Download PDF

Info

Publication number
US20130345147A1
US20130345147A1 US13/957,772 US201313957772A US2013345147A1 US 20130345147 A1 US20130345147 A1 US 20130345147A1 US 201313957772 A US201313957772 A US 201313957772A US 2013345147 A1 US2013345147 A1 US 2013345147A1
Authority
US
United States
Prior art keywords
therapeutically active
cyclosporin
active agent
keratoconjunctivitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/957,772
Inventor
Gregg Feinerman
Neil Barth
Rhett Schiffman
Pamela S. Barnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saint Regis Mohawk Tribe
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US13/957,772 priority Critical patent/US20130345147A1/en
Priority to US13/966,770 priority patent/US20140011751A1/en
Publication of US20130345147A1 publication Critical patent/US20130345147A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHIFFMAN, RHETT M., BARNETT, PAMELA S., FEINERMAN, GREGG, BARTH, NEIL
Assigned to SAINT REGIS MOHAWK TRIBE reassignment SAINT REGIS MOHAWK TRIBE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLERGAN, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Definitions

  • Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment.
  • patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
  • One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
  • administering means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered.
  • administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
  • Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof.
  • the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition.
  • the cyclosporin, analog or derivative thereof, or a combination thereof might be administered after the mammal has begun to receive the therapeutically active agent.
  • the cyclosporin, analog or derivative thereof, or a combination thereof might be administered after the mammal has ceased receiving the therapeutically active agent.
  • Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent.
  • any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
  • composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
  • kits may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit.
  • the agents may be packaged together.
  • the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages.
  • kit form the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
  • a cyclosporin, or an analog or derivative thereof, including cyclosporin A for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
  • a cyclosporin or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
  • a cyclosporin or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
  • Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
  • cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
  • nasolacrimal stenosis nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation (such as keratoconjunctivitis sicca), increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
  • Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
  • the ocular condition may be associated with any antiviral agent, the following
  • the ocular condition may be associated with any chemotherapy agent, the following
  • Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
  • Chemotherapeutic compounds incorporating this structure are thus contemplated.
  • the structures of paclitaxel and docetaxel are shown below.
  • the chemotherapy agent is docetaxel.
  • the ocular condition may be associated with any immunomodulator, the following
  • therapeutically active agents may cause lacrimal duct stenosis: docetaxel.
  • therapeutically active agents may cause keratoconjunctivitis: Capecitabine.
  • one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivi
  • the therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
  • a therapeutically active agent and cyclosporin A may be administered in a single composition.
  • compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. patent application Ser. No. 11/161,218, filed on Jul. 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
  • cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc.
  • the cyclosporin A is administered twice a day as indicated on the package insert.

Abstract

Therapeutic methods are disclosed herein.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This continuation application claims priority to: U.S. Provisional Patent Application No. 60/596,709, filed on Oct. 14, 2005; U.S. Provisional Patent Application No. 60/597,431, filed on Nov. 30, 2005; U.S. Provisional Patent Application, No. 60/805,577, filed on Jun. 22, 2006; U.S. patent application Ser. No. 11/548,631, filed Oct. 11, 2006, now U.S. Pat. No. 7,745,400; U.S. patent application Ser. No. 12/825,116, filed Jun. 28, 2010, now U.S. Pat. No. 8,501,174; and co-pending U.S. patent application Ser. No. 13/957,722, filed Aug. 2, 2013, all of which are expressly incorporated by reference herein.
  • DESCRIPTION OF THE INVENTION
  • Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment. In particular, patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
  • One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
  • “Administration of a therapeutically active agent to said mammal” means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered. Thus, administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
  • Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof. For example, the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has begun to receive the therapeutically active agent. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has ceased receiving the therapeutically active agent. Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent. Thus, any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
  • It may be convenient to provide a single pharmaceutical composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
  • It may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit. For example, the agents may be packaged together. For example, (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages. When in kit form, the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
  • Use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
  • Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
  • Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
  • Figure US20130345147A1-20131226-C00001
  • Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
  • Other cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
  • The ocular conditions to be prevented or treated are well known in the art. In particular, nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation (such as keratoconjunctivitis sicca), increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
  • Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
  • Although the ocular condition may be associated with any antiviral agent, the following
    • antiviral agents are contemplated in particular:
    • Zalcitabine, and
    • Rimantadine Hydrochloride.
  • Although the ocular condition may be associated with any chemotherapy agent, the following
    • chemotherapy agents are contemplated in particular:
    • Paclitaxel and derivatives thereof, such as Docetaxel
    • Doxorubicin Hydrochloride,
    • Irinotecan Hydrochloride,
    • Fluorouracil,
    • Imatinib Mesylate, and
    • Rituximab.
  • Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
  • Figure US20130345147A1-20131226-C00002
  • Chemotherapeutic compounds incorporating this structure are thus contemplated. For example, the structures of paclitaxel and docetaxel are shown below.
  • Figure US20130345147A1-20131226-C00003
  • In one embodiment, the chemotherapy agent is docetaxel.
  • Although the ocular condition may be associated with any immunomodulator, the following
    • immunomodulators are contemplated in particular:
    • Interferon alfa-2b, Recombinant
    • Mycophenolate Mofetil, and
    • Mycophenolate Mofetil Hydrochloride.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimal duct stenosis: docetaxel.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimation:
    • interferon alfa-2b, recombinant,
    • doxorubicin hydrochloride,
    • irinotecan hydrochloride,
    • fluorouracil,
    • docetaxel, and
    • zalcitabine.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause abnormal lacrimation:
    • mycophenolate motefil,
    • mycophenolate motefil hydrochloride,
    • imatinib mesylate,
    • ritumixab, and
    • rimantadine hydrochloride.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratitis:
    • Amantadine Hydrochloride,
    • Erlotinib,
    • Bexarotene, and
    • Voriconazole.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratoconjunctivitis: Capecitabine.
  • While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause conjunctivitis:
    • Risedronate Sodium,
    • Leflunomide,
    • Mycophenolate Mofetil,
    • Oxaliplatin,
    • Cetuximab,
    • Ribavirin,
    • Rituximab,
    • Basiliximab,
    • Erlotinib,
    • Capecitabine,
    • Doxorubicin Hydrochloride,
    • Imiquimod,
    • Amphotericin B, liposomal,
    • Zolpidem Tartrate,
    • Glatiramer Acetate,
    • Epirubicin Hydrochloride,
    • Saquinavir,
    • Enfuvirtide,
    • Imatinib Mesylate,
    • Gefitinib,
    • Lamotrigine,
    • Delavirdine Mesylate,
    • Rituximab,
    • Ivermectin,
    • Palivizumab,
    • Oseltamivir Phosphate,
    • Bexarotene,
    • Docetaxel,
    • Abacavir Sulfate,
    • Lamivudine,
    • Zidovudine,
    • Voriconazole,
    • Nevirapine,
    • Ribavirin, and
    • Abacavir Sulfate.
  • Additionally, one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivizumab, ribavirin, rimantadine hydrochloride, risedronate sodium, rituximab, saquinavir, voriconazole, zalcitabine, zidovudine, and zolpidem tartrate.
  • The therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
  • Alternatively, a therapeutically active agent and cyclosporin A may be administered in a single composition.
  • Useful compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. patent application Ser. No. 11/161,218, filed on Jul. 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
  • In one embodiment, cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc. The cyclosporin A is administered twice a day as indicated on the package insert.
  • Although there has been hereinabove described pharmaceutical compositions for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. Accordingly, any and all modifications, variations, or equivalent arrangements, which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.

Claims (9)

1.-11. (canceled)
12. A method comprising administering an ophthalmically acceptable emulsion comprising cyclosporin A to a mammal before the mammal receives a therapeutically active agent, wherein the therapeutically active agent comprises paclitaxel, and wherein the method is effective in treating abnormal lacrimation.
13. The method of claim 12, wherein the ophthalmically acceptable emulsion comprises cyclosporin A at a concentration of about 0.05%.
14. The method of claim 13, wherein the ophthalmically acceptable emulsion further comprises castor oil, polysorbate 80, and high molecular weight co-polymers of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol.
15. The method of claim 13, wherein the abnormal lacrimation is associated with keratoconjunctivitis.
16. The method of claim 13, wherein the abnormal lacrimation is the result of keratoconjunctivitis.
17. The method of claim 15, wherein the keratoconjunctivitis is associated with the therapeutically active agent.
18. The method of claim 16, wherein the keratoconjunctivitis is associated with the therapeutically active agent.
19.-24. (canceled)
US13/957,772 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin Abandoned US20130345147A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/957,772 US20130345147A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,770 US20140011751A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US59670905P 2005-10-14 2005-10-14
US59743105P 2005-11-30 2005-11-30
US80550906P 2006-06-22 2006-06-22
US80557706P 2006-06-22 2006-06-22
US11/548,631 US7745400B2 (en) 2005-10-14 2006-10-11 Prevention and treatment of ocular side effects with a cyclosporin
US12/825,116 US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,772 US20130345147A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/825,116 Continuation US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/966,770 Continuation US20140011751A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Publications (1)

Publication Number Publication Date
US20130345147A1 true US20130345147A1 (en) 2013-12-26

Family

ID=38263959

Family Applications (7)

Application Number Title Priority Date Filing Date
US11/548,631 Active US7745400B2 (en) 2005-10-14 2006-10-11 Prevention and treatment of ocular side effects with a cyclosporin
US12/825,116 Active 2027-06-08 US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,722 Abandoned US20140030226A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,772 Abandoned US20130345147A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,796 Abandoned US20140038904A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,744 Abandoned US20140010846A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,770 Abandoned US20140011751A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/548,631 Active US7745400B2 (en) 2005-10-14 2006-10-11 Prevention and treatment of ocular side effects with a cyclosporin
US12/825,116 Active 2027-06-08 US8501174B2 (en) 2005-10-14 2010-06-28 Prevention and treatment of ocular side effects with a cyclosporin
US13/957,722 Abandoned US20140030226A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/957,796 Abandoned US20140038904A1 (en) 2005-10-14 2013-08-02 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,744 Abandoned US20140010846A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin
US13/966,770 Abandoned US20140011751A1 (en) 2005-10-14 2013-08-14 Prevention and treatment of ocular side effects with a cyclosporin

Country Status (2)

Country Link
US (7) US7745400B2 (en)
TW (1) TW200735886A (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20140011750A1 (en) * 2005-10-14 2014-01-09 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
CA2701482C (en) 2007-10-08 2018-10-23 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
GB201514328D0 (en) * 2015-08-12 2015-09-23 Sigmoid Pharma Ltd Compositions
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
US20050282734A1 (en) * 1998-07-30 2005-12-22 Kadima Tenshuk A Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
US20060018910A1 (en) * 2004-07-16 2006-01-26 Pfizer Inc Combination treatment for non-hematologic malignancies

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (en) 1978-03-07 1979-09-13 Sandoz Ag NEW RESORBABLE GALENIC COMPOSITIONS
US4388229A (en) 1981-11-02 1983-06-14 Syntex (U.S.A.) Inc. Contact lens rejuvenating solution
US4533594A (en) 1983-12-16 1985-08-06 Porritts & Spencer Batt-on-mesh felt employing polyurethane-coated multifilaments in the cross-machine direction
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US4814323A (en) 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
JP2577049B2 (en) 1987-06-04 1997-01-29 三共株式会社 Cyclosporine preparation
KR920003601B1 (en) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 Ocular cyclosporin composition
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
HU201567B (en) 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (en) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 A multiphase cyclosporin composition
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
US7081445B2 (en) 1989-02-20 2006-07-25 Novartis Ag Cyclosporin galenic forms
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5294604A (en) 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
CA2048302A1 (en) 1990-08-15 1992-02-16 Victoria P. Meucci Solubilization reagent for biological test samples
MA22456A1 (en) 1991-03-05 1992-10-01 Procter & Gamble PERSONAL CLEANING PRODUCT OF THE SOFT, STABLE LIQUID SOAP TYPE AND METHOD FOR THE PREPARATION THEREOF
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
DK0589843T3 (en) 1992-09-25 2002-04-02 Novartis Ag Cyclosporin-containing pharmaceutical preparations
US20020107183A1 (en) 1993-04-20 2002-08-08 Monika Petszulat Pharmaceutical preparations comprising cyclosporin for oral administration
CH686761A5 (en) 1993-05-27 1996-06-28 Sandoz Ag Pharmaceutical formulations.
US20020099067A1 (en) 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
DE4340781C3 (en) 1993-11-30 2000-01-27 Novartis Ag Liquid preparations containing cyclosporin and process for their preparation
US5891846A (en) 1994-02-17 1999-04-06 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
KR0146671B1 (en) 1994-02-25 1998-08-17 김충환 Cyclosporin-containing powder composition
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5827835A (en) 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
CN1121238C (en) 1994-11-03 2003-09-17 诺瓦蒂斯有限公司 Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability and process for producing them
KR0167613B1 (en) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 Cyclosporin-containing soft capsule compositions
US5834017A (en) 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (en) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin containing preparations
US6787306B1 (en) * 1996-03-20 2004-09-07 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations
US5753166A (en) 1996-04-29 1998-05-19 Eastman Chemical Company Process of making a non-circular cross-sectional fiber
US5798333A (en) 1996-09-17 1998-08-25 Sherman; Bernard C. Water-soluble concentrates containing cyclosporins
SG115386A1 (en) 1997-01-30 2005-10-28 Novartis Ag Hard gelatine capsules containing pharmaceutical compositions substantially free of any oil
FR2762843B1 (en) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
EP1042341A1 (en) * 1997-11-25 2000-10-11 Protarga Inc. Nucleoside analog compositions and uses thereof
CA2313024C (en) 1997-12-10 2008-06-03 Severson, Mary L. Pharmaceutical compositions containing an omega-3 fatty acid oil
TWI241915B (en) 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
KR100336090B1 (en) 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
DE19835906A1 (en) 1998-08-07 2000-02-10 Basf Ag Process for the production of vinyl compounds
MXPA01005884A (en) 1998-12-11 2002-04-24 Pharmasolutions Inc Self-emulsifying compositions for drugs poorly soluble in water.
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
WO2001032142A1 (en) 1999-11-02 2001-05-10 Cipla Limited Cyclosporin formulation
DE19958684A1 (en) * 1999-12-06 2001-06-07 Knoll Ag Use of GD3 synthase inhibitors for the treatment of neuropathological disorders and methods for the identification of GD3 synthase inhibitors
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
DK1142566T3 (en) 2000-04-07 2004-02-09 Medidom Lab Ophthalmological formulations based on cyclosporine, hyaluronic acid and polysorbate
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CN1127955C (en) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 Medicine for treating immune relative disease of anterior chamber and surface of eye
ES2236481T3 (en) * 2001-01-16 2005-07-16 Glaxo Group Limited PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR CANCER TREATMENT.
AR033711A1 (en) 2001-05-09 2004-01-07 Novartis Ag PHARMACEUTICAL COMPOSITIONS
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
ITMI20012694A1 (en) 2001-12-19 2003-06-19 Remedia S R L PHARMACEUTICAL COMPOSITION INCLUDING A DOUBLE OIL / WATER / OIL MICROEMULSION INCORPORATED IN A SOLID SUPPORT
BR0215187A (en) 2001-12-20 2004-11-16 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporine, a hydrophilic surfactant and a lipophilic surfactant
KR100441167B1 (en) 2001-12-27 2004-07-21 씨제이 주식회사 Composition of microemulsion preconcentrate
KR20030065831A (en) 2002-02-01 2003-08-09 주식회사 태평양 cyclosporin-containing sustained release pharmaceutical composition
US20030225011A1 (en) * 2002-05-31 2003-12-04 Samuel David Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391471B (en) 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB2391472B (en) 2002-08-02 2004-12-08 Satishchandra Punambhai Patel Pharmaceutical compositions
AU2003277424A1 (en) * 2002-10-17 2004-05-04 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20040185068A1 (en) 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20050196370A1 (en) 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050043258A1 (en) * 2003-03-26 2005-02-24 Genteric, Inc. Methods of treating xerostomia and xerophthalmia
EP1624858B1 (en) 2003-04-09 2018-06-06 Rutgers, the State University of New Jersey Novel encochleation methods
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
AR047988A1 (en) * 2004-03-11 2006-03-15 Wyeth Corp ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB
EP1933832A2 (en) * 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
WO2008000085A1 (en) 2006-06-30 2008-01-03 The University Of Western Ontario Process for producing a concrete additive from an agricultural residue
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282734A1 (en) * 1998-07-30 2005-12-22 Kadima Tenshuk A Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin
US20030191179A1 (en) * 1999-10-25 2003-10-09 Supergen, Inc. Methods for administration of paclitaxel
US20060018910A1 (en) * 2004-07-16 2006-01-26 Pfizer Inc Combination treatment for non-hematologic malignancies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Akpek et al. A Randomized Trial of Topical Cyclosporin 0.05% in Topical Steroid-Resistant Atopic Keratoconjunctivitis. Ophthalmology. March 2004, Volume 111, Number 3, pages 476-482. *
Schmid et al. Update on Ocular Complications of Systemic Cancer Chemotherapy. Survey Of Ophthalmology. January-February 2006, Volume 51, Number 1, pages 19-40. *

Also Published As

Publication number Publication date
TW200735886A (en) 2007-10-01
US20100266622A1 (en) 2010-10-21
US20140010846A1 (en) 2014-01-09
US20070167358A1 (en) 2007-07-19
US8501174B2 (en) 2013-08-06
US20140038904A1 (en) 2014-02-06
US20140011751A1 (en) 2014-01-09
US7745400B2 (en) 2010-06-29
US20140030226A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
US20130345147A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US9603895B2 (en) Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en) Cyclosporin analogues
US8623814B2 (en) Antiviral agents
US8367053B2 (en) Cyclosporin analogues
NO334908B1 (en) Pharmaceutical preparation for the treatment of optic neuritis and its use.
US8349312B2 (en) Proline substituted cyclosporin analogues
US8236778B2 (en) Synergistic 5′-methylthioadenosine combinations
US8685917B2 (en) Cyclosporin analogues
US20130345148A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US10610565B2 (en) Prevention and treatment of ocular side effects with a cyclosporin
US20140011750A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US20140011752A1 (en) Prevention and treatment of ocular side effects with a cyclosporin
US9669095B2 (en) Cyclosporin analogues for preventing or treating hepatitis C infection
US8906853B2 (en) [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2013148155A1 (en) Compositions and methods for the treatment of dry eye disease
JPH0296521A (en) Remedy for immune disease
AU2013200652A1 (en) Cyclosporin analogues for preventing or treating hepatitis C infection

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FEINERMAN, GREGG;BARTH, NEIL;SCHIFFMAN, RHETT M.;AND OTHERS;SIGNING DATES FROM 20060911 TO 20061019;REEL/FRAME:034760/0393

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SAINT REGIS MOHAWK TRIBE, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALLERGAN, INC.;REEL/FRAME:043830/0446

Effective date: 20170908